About: Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up
Creator	Bove, Sergio Albini, Elena Beindorf, Eva Chiara, Rosa Cordioli, Cinzia Cossi, Stefania De Rossi, Nicola Filippini, Chiara Flamminio, Gigliola Giansiracusa, Paola Mancinelli, Manfredini, Silvano Mosca, Carlo Rasia, Sarah Rizzoni, Damiano Romanelli, Giuseppe Scarpazza, Cristina Scipione, Vittorio Vettoretto, Nereo
Source	Elsevier; Medline; PMC
abstract	BACKGROUND: Pneumonia with severe respiratory failure represents the principal cause of death in COVID-19, where hyper-inflammation plays an important role in lung damage. An effective treatment aiming at reducing the inflammation without preventing virus clearance is thus urgently needed. Tocilizumab, an anti-soluble IL-6 receptor monoclonal antibody, has been proposed for treatment of patients with COVID-19. METHODS: A retrospective cohort study at the Montichiari Hospital, Brescia, Italy, was conducted. We included consecutive patients with COVID-19 related pneumonia at the early stage of respiratory failure, all treated with a standard protocol (hydroxychloroquine 400 mg daily, lopinavir 800 mg plus ritonavir 200 mg per day). We compared survival rate and clinical status in a cohort of patients who received additional treatment with tocilizumab once (either 400 mg intravenous or 324 mg subcutaneous) with a retrospective cohort of patients who did not receive tocilizumab (referred to as the standard treatment group). All outcomes were assessed at the end of the follow-up, that correspond to death or complete recovery and discharge from the hospital. FINDINGS: 158 patients were included, 90 of which received tocilizumab. 34 out of 68 (50%) patients in the standard treatment group and 7 out of 90 (7.7%) in the tocilizumab group died. Tocilizumab significantly improved survival compared to standard care (multivariate HR: 0.057; 95% C.I = 0.017- 0.187, p < 0.001). No differences between the two administration routes of tocilizumab were observed. No tocilizumab-related infections and/or side effects were observed. INTERPRETATION: Early treatment with tocilizumab could be helpful to prevent excessive hyper-inflammation and death in COVID-19 related pneumonia. Low dose administration of tocilizumab is not associated with adverse events. FUNDING: none
has issue date	2020-07-17(xsd:dateTime)
bibo:doi	10.1016/j.eclinm.2020.100459
bibo:pmid	32838235
has license	no-cc
sha1sum (hex)	56f4f9d720c351dcd61497bb7d71d63ac1b83e19
schema:url	https://doi.org/10.1016/j.eclinm.2020.100459
resource representing a document's title	Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up
has PubMed Central identifier	PMC7366117
has PubMed identifier	32838235
schema:publication	EClinicalMedicine
resource representing a document's body	covid:56f4f9d720c351dcd61497bb7d71d63ac1b83e19#body_text
is schema:about of	named entity 'monoclonal antibody' named entity 'virus' named entity 'prevent' named entity 'pneumonia' named entity 'preventing' named entity 'Brescia' named entity 'day' named entity 'dose' named entity 'BRESCIA' named entity 'INFECTIONS' named entity 'LUNG' named entity 'BACKGROUND' named entity 'LOW DOSE ADMINISTRATION' named entity 'ADDITIONAL TREATMENT' named entity 'STANDARD' named entity '200' named entity 'RESPIRATORY FAILURE' covid:arg/56f4f9d720c351dcd61497bb7d71d63ac1b83e19 named entity 'Funding' named entity 'tocilizumab' named entity 'received' named entity 'Interpretation' named entity 'COVID-19' named entity 'retrospective cohort' named entity 'retrospective cohort study' named entity 'administration' named entity 'referred' named entity 'Methods' named entity 'pneumonia' named entity 'tocilizumab' named entity 'inflammation' named entity 'Pneumonia' named entity 'lopinavir' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'inflammation' named entity 'ritonavir' named entity 'virus' named entity 'monoclonal antibody' named entity 'COVID-19' named entity 'COVID' named entity 'tocilizumab' named entity 'routes' named entity 'monoclonal antibody' named entity 'cannula' named entity 'tocilizumab' named entity 'white blood cells' named entity 'Chicago' named entity 'tocilizumab' named entity 'pharmacological effect' named entity 'tocilizumab' named entity 'pro-inflammatory cytokines' named entity 'tocilizumab' named entity 'Helsinki' named entity 'hepatotoxicity' named entity 'clinical characteristics' named entity 'mechanical ventilation' named entity 'procalcitonin' named entity 'Mann-Whitney U test' named entity 'interleukin' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'COVID'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software